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Objectives: Integrase strand transfer inhibitors (INSTIs) are the latest class of antiretroviral drugs that prevent the 
integration of proviral DNA into the host genome. The aim of this study was to describe, for the first time, INSTI 
resistance mutations observed in Croatian HIV-infected patients.  
Methods: The study was conducted between March 2016 and September 2018 and included 4 previously untreated 
patients (antiretroviral, ARV-naive) as well as 18 unsuccessfully treated HIV-infected patients (ARV-experienced) that 
have been tested for INSTI resistance. The genetic data on INSTI resistance was obtained by population-based 
sequencing of the integrase gene. Resistance analysis to other classes of antiretroviral drugs has been performed in 
some patients by sequencing the protease gene and a part of the reverse transcriptase HIV-1 gene. 
Results: INSTI resistance mutations were not found in ARV-naive patients. Mutations associated with resistance to 
INSTIs have been observed in 5 of 18 (27.8%) patients failing INSTI-based ARV regiment. Resistance to INSTIs in 
ARV-experienced patients was attributed to major resistance mutations Q148R, N155H and E92Q that confer 
resistance to two INSTIs (raltegravir and elvitegravir).  
Conclusions: The results of this study describe the first 5 cases of ARV-experienced HIV-1 infected patients with 
clinically significant resistance to INSTIs, and emphasize the need for continuous surveillance of INSTI resistance in 
patients experiencing virological failure to antiretroviral treatment in Croatia.  
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Croatia is a country with a centralized system of 
clinical care where all patients living with human 
immunodeficiency type 1 (HIV-1) infection are treated 
and monitored at the University Hospital for Infectious 
Diseases "Dr. Fran Mihaljevic" (UHID) in Zagreb.
1
 
Additionally, surveillance of HIV resistance to 




ART suppresses HIV-1 replication to undetectable 
levels and enables immunological reconstitution in 
treated patients.
3
 Currently, there are six distinct 
classes of ART that can be classified based on their 
molecular mechanism and resistance profile: 
nucleoside-analogue reverse transcriptase inhibitors 
(NRTI), non-nucleoside reverse transcriptase inhibitors 
(NNRTI), protease inhibitors (PI), integrase inhibitors 
(INSTI), fusion inhibitors, and CCR5 antagonist. First-
line ART consists of three or more antiretroviral drugs, 
usually two NRTIs in combination with one integrase 
inhibitor (recommended by the International AIDS 
Society-USA Guidelines, IAS-USA) or 3 INSTIs with 




INSTIs are the most recently approved class of ART 
that exhibit exceptionally favorable characteristics of 
antiviral drugs including a high barrier to resistance 
(dolutegravir, bictegravir), good tolerability and high 
antiviral potency. Therefore, INSTIs quickly became 
an essential part of first-line ART regimens 
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recommended by European AIDS Clinical Society 
(EACS) guidelines as well as by other professional 
societies within the field.
6, 7
  
INSTIs prevent the integration of proviral DNA into 
the host genome by inhibiting the strand-transfer 
activity of HIV-1 integrase (IN).
8
 Currently, there are 
four INSTIs approved by the Food and Drugs 
Administration and the European Medicines Agency: 
raltegravir (RAL), elvitegravir (EGV), dolutegravir 
(DTG) and bictegravir (BIC). As of 2015, RAL, EVG 
and DTG are the INSTIs available in Croatia.  
Despite being highly effective in the treatment of HIV, 
resistance mutations occur in patients treated with the 
first generation of INSTIs (RAL and EGV), while data 
on primary resistance to these drugs (in previously 
untreated patients) are scarce.
9, 10
 The appearance of 
major resistance mutations accompanied by further 
accumulation of secondary resistance mutations leads 
to the development of clinically significant 
resistance.
11, 12
 Resistance to RAL has been extensively 
studied in the Benchmark trial in which the N155H, 
Q148H/K/R and Y143R pathways were identified.
13
 
Cross resistance between RAL and EVG has been 
described, and they are known to have a low genetic 
barrier which leads to the development of resistance 
with a single mutation.
14, 15
 Reduced susceptibility to 
RAL is associated with at least 3 distinctive genetic 
pathways that are defined by a signature mutation 
Y143R/H/C, Q148H/K/R or N155H and one or more 
additional mutations (13). Major resistance mutations 
for EVG include T66I, E92Q, Q148H/K/R, and 
N155H.
14, 15
 Several mutations are required in HIV 
integrase to confer high-level resistance to DTG. 
Dolutegravir has a higher genetic barrier to resistance 
than elvitegravir and raltegravir, but Q148H/K/R 
mutation in combination with other additional 
mutations could reduce its long-term potency.
16
 The 
R263K mutation was the first mutation rarely found 
selected at time of virological failure in patients failing 
a first-line dolutegravir-based treatment.
17
 
Current guidelines (DHHS, EACS, IAS-USA) 
recommend HIV-1 drug resistance testing for all HIV -
1-infected patients prior to therapy initiation. Primary 
resistance testing to INSTIs as a part of routine clinical 
diagnostics is not currently recommended.
5, 7, 16
 INSTI 
resistance testing has been introduced at the 
Department of Immunological and Molecular 
Diagnostics of UHID in 2016, and the majority of it is 
performed in patients with virological failure, as HIV-
infected patients failing antiretroviral therapy should be 
carefully monitored. In clinical practice in Croatia, 
primary resistance to INSTIs is performed individually 
in ARV-naive patients. The aim of this study was to 
describe, for the first time, INSTI resistance mutations 
observed in Croatian HIV-infected patients. 
MATERIAL AND METHODS 
Study population 
The present study was conducted between March 2016 
and September 2018 and included 22 samples: 4 from 
ARV-naive and 18 from HIV-experienced patients 
failing therapy. Clinical and laboratory characteristics 
of the patients are presented in Table 1. The data used 
in this study was extracted from the Database of the 
Croatian Reference center for HIV/AIDS that contains 
information on all HIV-infected patients from Croatia. 
In the study period, some patients were tested more 
than once, and for 5 patients both primary and 
secondary resistance testing was available. 
 
 
Table 1. Clinical and laboratory characteristics of patients 
enrolled in the study 
Characteristics  
Patient, n (antiretroviral naive/experienced) 22 (4/18) 
Gender males/females, n (%) 
3/19 
(13.6%/86.4%) 
CD4+ count/ µL of blood, median (range) 147 (6-2,105) 
HIV-1 RNA log10, median (range) 4.23 (3.42-7) 
Acquisition route, n (%)  
   Heterosexual contact 2 (9.1%) 
   Homosexual contact (male) 19 (86.4%) 
   Mother to child transmission 1 (4.5%) 
HIV-1 subtype, n (%)  
   Subtype B 21 (95.5%) 
   Subtype C 1 (4.5%) 
n - number of individuals 
 
 
Antiretroviral resistance testing 
Resistance to antiretroviral drugs in HIV-infected 
patients was performed by population-based 
sequencing of genes coding for enzymes that are the 
molecular targets of drugs. Isolation of total viral RNA 
from the plasma of HIV-infected patients as well as 
amplification of targeted genes were performed by 
using ViroSeq HIV-1 Genotyping System according to 
the manufacturer’s instructions (Applied Biosystems, 
USA).  
The genetic data obtained by population-based 
sequencing of HIV- 1 integrase gene (codons 1-288) 
was performed by using ViroSeq™ HIV-1 Integrase 
Genotyping kit (Abbott Molecular, USA) on ABI 
Prism 310 Genetic Analyser (Applied Biosystems, 
USA). Resistance to NRTI, NNRTI and PI was 
performed by sequencing the protease gene (codons 1-
99) and a part of reverse transcriptase gene (codons 1-
335) by using Viroseq HIV-1 Genotyping System v2.0. 
(Applied Biosystems, USA).  
INSTI resistance mutations were scored according to 
the International AIDS Society-USA Drug Resistance 
Mutations Group recommendations. Clinical 
significance of detected mutations was analyzed by 
using a bioinformatic tool Stanford University HIV 
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Drug Resistance Database (version 8.6.1.). HIV 
genotyping was performed by using the Rega algorithm 
for the use of genotypic HIV-1 resistance data (version 




INSTI resistance mutations were found only in samples 
of ARV-experienced patients (n=5). Mutations Q148R, 
N155H and E92Q were detected as major resistance 
mutations associated with RAL and EVG. Possible 
resistance to DTG was detected in one sample 
(mutation Q148R). The overall prevalence of INSTI 
resistance mutations in ARV-experienced patients was 
27.8% (5/18) (Table 2). Furthermore, treatment status 
of these five patients at resistance testing were 
tenofovir/emtricitabin+raltegravir (patients 1, 2, 4 and 
5), and elvitegravir/cobicistat/emtricitabine/tenofovir 
alafenamide (patient 3). 
 
 
Table 2. INSTI resistance mutation analysis in Croatian patients 
Patients Prevalence of resistance     
n (%) 
Antiretroviral naive (n=4) / 
Antiretroviral experienced (n=18) 5 (27.8%) 
INSTI mutations  
   Q148R 1 (5.6%) 
   N155H 2 (11.1%) 
   E92Q 2 (11.1%) 
n - number of individuals 
 
 
Primary resistance testing to INSTI was available for 3 
of 5 patients with INSTI resistance mutations, and no 
primary resistance mutations were found. 
For 19/22 samples included in the study, resistance 
analysis to other classes of antiretroviral drugs was 
available.   
In addition to INSTI resistance testing, samples of 
ARV-experienced patients with observed resistance to 
INSTIs were also analyzed to NRTI, NNRTI and PI 
resistance mutations. Four different drug resistance 
patterns (M184V/I, K65R, K70E, T69N) for NRTI, 
five different patterns for NNRTI (V90I, V106I, K10E, 
E138K, V179D) and one (Q58E) for PI were found 
(Table 3). Resistance to the NRTI class of drugs was 
detected in four of these samples, and in one sample 
(patient 5) multi-class resistance was observed.  
According to the HIV-1 subtyping results, subtype B 
was found in 21/22 samples (95.5%). The one non-B 




The results of this study have shown, for the first time, 
the prevalence and patterns of INSTI resistance 
mutations observed in HIV-1 infected Croatian 
patients. The results of this study also emphasize that 
naturally occurring mutations or substitutions 
conferring resistance to INSTIs are rare.  
The European SPREAD HIV resistance surveillance 
program published the results of a multicenter, cross-
sectional study in which the prevalence of INSTI 
resistance was evaluated by population sequencing of 
the integrase gene to determine whether spontaneously 
generated INSTI-resistant mutants could be circulating 
as minority species.
18
 No signature INSTI mutations 
were detected, whereas integrase substitutions were 
found in 14.3% individuals. These results showed that 
no INSTI resistant variants were circulating in Europe 
before the introduction of INSTIs in clinical practice in 
2007.
18
 On the other hand, polymorphisms that could 
contribute to INSTI resistance were frequent.
18
  
There is limited number of studies analyzing 
transmitted drug resistance (in previously untreated 
patients) to INSTIs. Recent studies show very low 
prevalence of major resistance mutations (ranging 
between 0%-0.33%) in Austria, Veneto region of Italy, 
part of Canada, several African countries and USA. 




Performing integrase genotyping before initiating 
INSTI therapy is not required, but resistance testing in 
individuals failing INSTI therapy is clinically 
warranted. In this study, major RAL and EVG 
resistance mutations (Q148R, N155H, E92Q) rates 
were 27.8% in ARV- experienced patients. These are 
the first cases of patients experiencing virological 
 
 
Table 3. Drug resistance mutation patterns in ARV-experienced patients with observed resistance to INSTIs 
Patient INSTI mutations Resistance to INSTIs RT/PI mutations Resistance to RT/PIs 
Patient 1 Q148R RAL, EVG, DTG (PR) M184I, T69N, V90I, V106I FTC, 3TC 
Patient 2 N155H RAL, EVG M184V FTC, 3TC 
Patient 3 E92Q EVG, RAL (PR) M184V, K65R, K70E FTC, 3TC, ddI, TDF, d4t, ABC 
Patient 4 N155H RAL, EVG M184I, V179D FTC, 3TC 
Patient 5 E92Q EVG, RAL (PR) M184I, K101E, E138K, Q58E FTC, 3TC, RPV, ETR(PR), EFV(PR), NVP (PR) 
INSTI-integrase strand transfer inhibitors, RT-reverse transcriptase inhibitors; PI-protease inhibitors; ARV-antiretroviral; RAL-raltegravir, EVG-
elvitegravir; DTG-dolutegravir; FTC-emtricitabine; 3TC-lamivudine; ddI-didanosine; TDF-tenofovir; d4T-stavudine, ABC-abacavir; RPV-rilpivirine; 
ETR-etravirine; EFV-efavirenz; NVP-nelvirapine; PR-possible resistance 
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failure with clinically significant resistance to RAL and 
EVG that have been detected in Croatia. Therefore, 
continuous surveillance of INSTI resistance in 
virological failures in Croatia is necessary, and 
resistance testing must be a routine practice in INSTI 
treatment management. 
The results of HIV-1 resistance to NRTI, NNRTI and 
PI with various mutation patterns observed in the study 
reflect the repertoire of drugs that are available in 
Croatia prior to the introduction of INSTIs, and show 
multi-class drug resistance that regretfully includes all 
ARV drug class options. These results confirm that the 
use of INSTIs as a treatment of choice in Croatia 
should be encouraged.  
The majority of HIV-infected patients in Croatia are 
infected with subtype B, but non-B subtypes have also 
been observed, mostly in the heterosexual patient 
group. The results of this study confirm a high 




Virological failure occurs frequently in routine clinical 
practice and is associated with accumulation of 
mutations leading to increasing levels of drug 
resistance.
25
 Drug resistance reduces therapeutic 
options and the results of this study emphasize the 
importance of selecting the appropriate therapy when 
managing ARV-experienced patients by taking into 
account resistance testing results. Due to the high 
genetic barrier to resistance, second generation INSTIs 
(e.g. DVG or BIC) are viable treatment options for 
ART-experienced patients failing therapy. This concept 
is also supported by the results of our study showing 
possible resistance to DVG in only one patient. In 
conclusion, the results of this study emphasize the need 
for continuous surveillance of INSTI resistance in 
patients experiencing virological failure to 
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